ABBV-951
Showing 1 - 25 of 121
Subcutaneous Infusion of ABBV-951 to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Jun 15, 2023
ABBV-951 Subcutaneous Infusion to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Oct 25, 2023
Parkinson's Disease Trial in United States (ABBV-951)
Recruiting
- Parkinson's Disease
- ABBV-951
-
Aurora, Colorado
- +9 more
Jun 7, 2022
Parkinson's Disease (PD) Trial in Australia, United States (ABBV-951)
Enrolling by invitation
- Parkinson's Disease (PD)
- ABBV-951
-
Birmingham, Alabama
- +52 more
Oct 17, 2022
Parkinson's Disease (PD) Trial in Worldwide (ABBV-951)
Completed
- Parkinson's Disease (PD)
- ABBV-951
-
Birmingham, Alabama
- +64 more
Sep 23, 2022
Parkinson's Disease (PD) Trial in Worldwide (ABBV-951)
Enrolling by invitation
- Parkinson's Disease (PD)
- ABBV-951
-
Birmingham, Alabama
- +49 more
Jan 18, 2022
Parkinson's Disease (PD) Trial in United States (ABBV-951)
Completed
- Parkinson's Disease (PD)
- ABBV-951
-
Glendale, California
- +6 more
Nov 13, 2019
Parkinson's Disease (PD) Trial in United States (ABBV-951)
Completed
- Parkinson's Disease (PD)
- ABBV-951
-
Sun City, Arizona
- +11 more
Mar 12, 2019
Progressive Supranuclear Palsy Trial in Worldwide (Placebo, ABBV-8E12)
Terminated
- Progressive Supranuclear Palsy
- Placebo
- ABBV-8E12
-
Birmingham, Alabama
- +65 more
Feb 1, 2021
Healthy Volunteers Trial in Glendale (TAK-951 Placebo, TAK-951)
Completed
- Healthy Volunteers
- TAK-951 Placebo
- TAK-951
-
Glendale, CaliforniaCalifornia Clinical Trials Medical Group
Oct 11, 2022
Advanced Solid Tumors Cancer Trial in Worldwide (ABBV-151, Budigalimab)
Recruiting
- Advanced Solid Tumors Cancer
-
New Haven, Connecticut
- +29 more
Dec 5, 2022
Upper Limb Spasticity Trial (ABBV-950, BOTOX, Placebo for ABBV-950)
Not yet recruiting
- Upper Limb Spasticity
- ABBV-950
- +2 more
- (no location specified)
Jul 14, 2023
ABBV-154 Trial in Grayslake, Las Vegas (ABBV-154 Dose Formulation A, ABBV-154 Dose Formulation B)
Active, not recruiting
- ABBV-154
- ABBV-154 Dose Formulation A
- ABBV-154 Dose Formulation B
-
Grayslake, Illinois
- +1 more
Dec 19, 2022
Unresectable Metastatic Colorectal Cancer Trial (ABBV-400, Bevacizumab, Folinic Acid)
Not yet recruiting
- Unresectable Metastatic Colorectal Cancer
- ABBV-400
- +4 more
- (no location specified)
Oct 25, 2023
DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +3 more
-
Louisville, Kentucky
- +6 more
Nov 14, 2022
Relapsed/Refractory Multiple Myeloma Trial in Japan (ABBV-383)
Recruiting
- Relapsed/Refractory Multiple Myeloma
-
Kashiwa-shi, Chiba, Japan
- +5 more
Jan 25, 2023